News | December 16, 2025
Sanofi secures two breakthrough nods in China for rare blood disorders
Qfitlia is the first antithrombin (AT)-lowering therapy approved for routine prophylaxis in hemophilia
Qfitlia is the first antithrombin (AT)-lowering therapy approved for routine prophylaxis in hemophilia
Alphyn is developing Zabalafin Hydrogel as the first therapy to simultaneously tackle the interconnected drivers of AD
Roche says its new assay “resolves this challenge by delivering accurate and specific results
The patented product, developed by Venus Medicine Research Centre (VMRC) for the treatment of multidrug-resistant (MDR) infections, was sold to Cipla in 2019
Captured microbes are then neutralized on engineered microbicidal surfaces
The PCR-based test, delivered via Roche’s cobas liat system, allows results to be obtained during a patient consultation in GP practices and Emergency Rooms
Despite steep funding setbacks, the global HIV response has gained momentum in 2025 with the introduction of twice-yearly injectable LEN
In 2024, 59 countries reported large or disruptive measles outbreaks – nearly triple the number reported in 2021 and the highest since the onset of the COVID-19 pandemic
The oral, film-coated tablet is licensed for patients whose cancer has returned during or shortly after hormone therapy
The Complement Laboratory is equipped with state-of-the-art immunoturbidimetric and ELISA platforms and adheres to CAP and NABL accreditation standards
Subscribe To Our Newsletter & Stay Updated
